Na Semax

What NA-Semax Is NA-Semax is a chemically modified version of Semax, itself a synthetic peptide developed in the Soviet Union/Russia in the 1980s. Semax is derived from a fragment of ACTH(4-10) — a small piece of adrenocorticotropic hormone — with additional amino acids (Pro-Gly-Pro) attached to protect it from rapid enzymatic breakdown. NA-Semax adds an acetyl group to the N-terminus of the Semax molecule. This modification is intended to: Increase resistance to enzymatic degradation Potentially extend the peptide's duration of action in the body Possibly alter its potency or receptor interaction compared to standard Semax It's marketed as an "improved" or longer-lasting version of the original, though independent verification of these claims is limited. Proposed Mechanism of Action Semax (and by extension, NA-Semax) doesn't act like the hormone it's derived from (ACTH) in terms of adrenal stimulation. Instead, research points to effects on the central nervous system, including: Increasing BDNF (brain-derived neurotrophic factor) expression, which supports neuron growth, survival, and synaptic plasticity Modulating dopamine and serotonin systems, potentially affecting mood, focus, and motivation Influencing NGF (nerve growth factor) pathways Antioxidant and anti-inflammatory effects in neural tissue Possible effects on cerebral blood flow Areas of Research Interest Area What's Being Studied Cognitive enhancement Most popular use — attention, memory, learning studied in Russian research and animal models Stroke recovery One of Semax's most established clinical uses in Russia — used post-ischemic stroke to support recovery ADHD-like symptoms Some Russian clinical use for attention disorders in children Neuroprotection Explored for protecting neurons during oxidative stress or injury Optic nerve conditions Some Russian clinical use for optic nerve atrophy Mood/anxiety Anecdotal and some preclinical interest, not well established Current Evidence Base Standard Semax: Has a meaningful body of Russian clinical research and use, including some human trials, primarily for stroke recovery and cognitive/attention disorders. It has decades of documented use within Russian medicine. NA-Semax specifically: Has substantially less independent research than standard Semax. Most claims about its enhanced potency or duration come from anecdotal user reports and manufacturer marketing rather than peer-reviewed comparative studies. Western clinical trials: Essentially nonexistent for either version — most rigorous data comes from Russian-language studies that haven't been widely replicated or validated by Western regulatory bodies (FDA, EMA)

Pairs well with